Wire · opportunities
Merck gets FDA approval for first oral PCSK9 cholesterol pill
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 16 July 2026 · Fusion42 review
Merck received FDA approval for Lipfendra (enlicitide), the first once-daily oral PCSK9 inhibitor for lowering LDL cholesterol, reducing it by up to 59% in trials and directly competing with injectable alternatives from Amgen, Regeneron, and Sanofi.
This Wire brief sits within Fusion42's coverage of Digital Health.
◆ ◆ The Wire takeaway
If you build patient adherence software, data platforms, or digital therapeutics for chronic disease, Merck just handed injectables their exit date. The move from needle to daily pill reshapes the entire care workflow - and every incumbent injectable maker now needs to rebuild distribution, patient support, and pricing strategies for an oral world.
◆ Coverage
1 source · 16 Jul 2026
◆ Related on Wire
◆ Topics